论文部分内容阅读
医学论坛网报道,近日广州医学院附属广州市第一人民医院消化内科欧娅、贾林、邱嘉华等人共同发表论文,旨在探讨infliximab(TNF-α单抗)对大鼠急性坏死性胰腺炎(ANP)并多器官功能障碍综合征(MODS)模型肠动力及肠屏障损害的保护作用。研究指出,早期使用infliximab可有效改善ANP大鼠的胃肠动力功能及减轻肠屏障损害。该文发表在2012年第12卷第1期《中华胰腺病杂志》上。30只SD大鼠按完全随机法分为假手术组、ANP组和infliximab组。经胰胆管逆行注射4.5%牛磺胆酸钠制备大鼠ANP
Medical Forum Network reported recently Guangzhou Medical College Affiliated Guangzhou City People’s Hospital of Digestive Medicine Ou Ya, Jialin, Qiu Jiahua and others co-published papers aimed to investigate infliximab (TNF-α monoclonal antibody) on acute necrotizing pancreatitis (ANP) and multiple organ dysfunction syndrome (MODS) model of intestinal motility and intestinal barrier damage. Studies indicate that early use of infliximab can effectively improve gastrointestinal motility and reduce intestinal barrier damage in ANP rats. This article was published in 2012, Volume 12, No. 1 “Chinese Pancreas Diseases”. Thirty SD rats were randomly divided into sham operation group, ANP group and infliximab group. Rat ANP was prepared by retrograde injection of 4.5% sodium taurocholate into the pancreatic duct